Updated:
Design Therapeutics
Design Therapeutics was formed in 2017 by Dr. Pratik Shah and a scientific team aiming to treat serious degenerative disorders caused by nucleotide repeat...
Design Therapeutics
Design Therapeutics was formed in 2017 by Dr. Pratik Shah and a scientific team aiming to treat serious degenerative disorders caused by nucleotide repeat expansions. The company's approach centers on its GeneTAC platform, which uses small molecules to resolve the dysfunctional DNA-protein complexes that drive disease at the transcriptional level. Shah, formerly president of Auspex Pharmaceuticals before its sale to Teva, brought both the rare-disease development experience and the transaction track record that informed Design's path from lab to public markets. Design deploys its capital entirely toward advancing a single-asset-class pipeline of preclinical and clinical-stage precision therapeutics. Its lead program, DT-216, is a GeneTAC small molecule designed to restore frataxin protein levels in patients with Friedreich's ataxia. A Phase 1 clinical trial for DT-216 dosed its first patient in 2021. The company has also nominated development candidates aimed at Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1, two other nucleotide-repeat disorders with significant unmet medical need. The geographic scope is concentrated in the United States, with clinical trial operations initiated domestically (per the firm's regulatory filings). The firm went public on the Nasdaq under ticker DSGN in March 2021, pricing shares at $20 and raising $276 million in the offering, according to Renaissance Capital. As of its most recent proxy statement, the organization maintains a lean management structure led by Shah, with Scientific Co-founder Dr. Rodney Lappe serving as Chief Scientific Officer. The company has not disclosed plans for adjacent investment vehicles or a philanthropic foundation, operating with the straightforward governance structure typical of a publicly traded biotech platform. Its structural differentiator lies in the mechanism of action: GeneTAC molecules are designed to intervene at the junction of the repetitive DNA and transcription machinery itself, rather than degrading downstream RNA or replacing the mutated protein. This upstream intervention targets the root cause of the genetic lesion, distinguishing the platform from antisense oligonucleotide or gene therapy approaches that dominate much of the rare-disease landscape.
General information
Firm type
Asset Manager
Year founded
2017
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Carlsbad
Corporate office
Carlsbad, CA, United States
Principals
Pratik Shah
Chairman and CEO
Rodney Lappe
Chief Scientific Officer
Sector focus
Frequently asked questions
Who runs investment and strategic decisions at Design Therapeutics?
Strategic and capital-allocation decisions are led by Chairman and CEO Dr. Pratik Shah, who co-founded the company in 2017. Shah was previously president of Auspex Pharmaceuticals, a rare-disease biotech acquired by Teva for $3.5 billion in 2015 (per the firm's disclosures). The board of directors, common for a publicly traded Nasdaq company, provides governance oversight on major deployment moves.
Is Design Therapeutics a family office or does it operate more like a biotech venture?
Design Therapeutics is not a family office or investment fund. It is a clinical-stage, publicly traded biotechnology company that raised capital through a traditional Series A-to-IPO path — including backing from RA Capital, SR One, and Quan Capital — and now deploys its own balance sheet toward internal drug programs.
Does Design Therapeutics commit to external funds or only direct development programs?
The firm does not make fund commitments or act as a limited partner. All deployment funds its own internal GeneTAC platform and pipeline, with 100% of resources allocated to direct research and development programs in its own labs.
What is the GeneTAC platform and how does it differ from gene therapy?
GeneTAC, or Gene Targeted Chimera, molecules are small, orally delivered drugs that bind directly to the aberrant DNA-repeat structures that cause transcription to stall. Unlike traditional gene therapies that deliver replacement genes via viral vectors or antisense oligonucleotides that degrade RNA, GeneTACs are designed to correct the genetic lesion at the transcriptional source (per the firm's scientific publications, 2020-2021).
What investment stages or partnership structures does Design Therapeutics typically employ?
The firm is currently a fully proprietary developer and does not pursue structured co-investment partnerships or syndicate-style special-purpose vehicles typical of venture firms. All pipeline assets are wholly owned. Any future licensing or co-development agreements with large pharmaceutical partners would be a strategic pivot from the current model.
Which disease indications does Design Therapeutics explicitly target?
The pipeline is focused on nucleotide repeat expansion disorders. The lead indication is Friedreich's ataxia, a fatal neurodegenerative disease caused by a GAA repeat expansion in the FXN gene. The company has also disclosed programs for Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1 (per the firm's investor communications).
How is the scientific team structured and who leads the research?
The research effort is led by Co-founder and Chief Scientific Officer Dr. Rodney Lappe, with platform technology originally developed in the labs of Dr. Joel Gottesfeld at The Scripps Research Institute, from which the company exclusively licensed the foundational GeneTAC intellectual property.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: